Proniosomal powder of captopril: Formulation and evaluation

被引:26
作者
Gupta, Ankur [1 ]
Prajapati, Sunill Kr. [1 ]
Singh, Mamta [1 ]
Balamurugan, M. [1 ]
机构
[1] Jaipur Coll Pharm, Jaipur 302022, Rajasthan, India
关键词
niosomes; proniosomes; captopril; sorbitol;
D O I
10.1021/mp0700110
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The aim of the present study was to design a proniosomal drug delivery system of captopril to overcome the limitations of conventional dosage form and to optimize encapsulation parameters to achieve a delivery system suitable for in vitro investigations. Proniosomes are dry powders, which makes richer processing and packing possible. A surfactant coated carrier method was utilized to formulate proniosomal powder containing captopril as a model drug. This system was evaluated in vitro for drug loading, vesicle size, angle of repose, encapsulation efficiency, and stability studies. This method of proniosome loading resulted in 54.16-70.10% of encapsulation. This study examined critical parameters such as type and composition of surfactant. Proniosomes were investigated by transmission electron microscopy for characterization. Four week stability data for proniosomal powder is reported, and at all sampling points significantly higher drug retention was observed. Thus, it can be concluded that the encapsulation of captopril in proniosomes facilitates the controlled release and constitutes a good choice.
引用
收藏
页码:596 / 599
页数:4
相关论文
共 16 条
[1]  
Bhatia A, 2004, J PHARM PHARM SCI, V7, P252
[2]   Maltodextrin-based proniosomes [J].
Blazek-Welsh, AI ;
Rhodes, DG .
AAPS PHARMSCI, 2001, 3 (01) :art. no.-1
[3]   CAPTOPRIL - AN UPDATE OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC USE IN HYPERTENSION AND CONGESTIVE HEART-FAILURE [J].
BROGDEN, RN ;
TODD, PA ;
SORKIN, EM .
DRUGS, 1988, 36 (05) :540-600
[4]   LIPID COMPOSITION AND PERMEABILITY OF LIPOSOMES [J].
DEGIER, J ;
MANDERSLOOT, JG ;
VANDEENE.LL .
BIOCHIMICA ET BIOPHYSICA ACTA, 1968, 150 (04) :666-+
[5]   Proniosomes: A novel drug carrier preparation [J].
Hu, CJ ;
Rhodes, DG .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1999, 185 (01) :23-35
[6]   CAPTOPRIL PHARMACOKINETICS, BLOOD-PRESSURE RESPONSE AND PLASMA-RENIN ACTIVITY IN NORMOTENSIVE CHILDREN WITH RENAL SCARRING [J].
LEVY, M ;
KOREN, G ;
KLEIN, J ;
MCLORIE, G ;
BALFE, JW .
DEVELOPMENTAL PHARMACOLOGY AND THERAPEUTICS, 1991, 16 (04) :185-193
[7]   Preparation and evaluation of liposomal formulations of tropicamide for ocular delivery [J].
Nagarsenker, MS ;
Londhe, VY ;
Nadkarni, GD .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1999, 190 (01) :63-71
[8]   Recent progress in sustained/controlled oral delivery of captopril: an overview [J].
Nur, AO ;
Zhang, JS .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2000, 194 (02) :139-146
[9]  
Saraf DK, 2003, INDIAN J PHARM SCI, V65, P620
[10]   QUALITY-OF-LIFE AND ANTIHYPERTENSIVE THERAPY IN MEN - A COMPARISON OF CAPTOPRIL WITH ENALAPRIL [J].
TESTA, MA ;
ANDERSON, RB ;
NACKLEY, JF ;
HOLLENBERG, NK .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (13) :907-913